Developing MuSK L-CBA to Detect Anti-MuSK Antibody
Consultant for argenx.Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Immunovant.Dr. Habib has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB.Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer.Dr. Habib has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech/Roche.Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NMD Pharma.Dr. Habib has received personal compensation in the range of $500-$4,999 for serving as a
Authors
- Ali Mousavi
- Hans Frykman (ORCID: https://orcid.org/0000-0002-6863-5614)
- Sazan Ismael
Publication Details
- Journal
- Neurology
- Published
- 2024-10-08
- DOI
- https://doi.org/10.1212/01.wnl.0001051812.74333.51
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Sanofi
- Muscular Dystrophy Association
- Alexion Pharmaceuticals
- F. Hoffmann-La Roche
- Regeneron Pharmaceuticals
- Amicus Therapeutics
- Audentes Therapeutics
- Argenx
- National Institutes of Health
- Genentech
- Spark Therapeutics
- National Institute of Neurological Disorders and Stroke